About Us
The Synektik Group is focused on bringing a whole range of innovative and cutting edge solutions to the medical market. The company has been operating since 2001. It carries a highly diversified portfolio of products and services for the medical field, both for diagnostic and therapeutic purposes. In particular, it covers fields of radiology, oncology, cardiology and neurology, while additionally pursuing its own research and development activities.
Currently, the Group operates in Poland, as well as in the Czech Republic, Slovakia, Ukraine and the Baltic states. The parent company, Synektik SA, is listed on the Warsaw Stock Exchange.
Human life and health as the absolute priority for Synektik
Our company fulfils its mission by means of delivering the highest quality products, services and medical solutions for the benefit of human health and life.
Stability and innovation
We aim to be seen as a regular partner and a leading supplier of innovative products and services as well as high technology solutions, all of which help medical establishments to improve their functionality, increase reliability and efficiency.
What distinguishes the Synektik Group?
Discover the components that enable us to build value for our customers, partners, and employees.
-
Modern solutions
Synektik Group provides market-leading IT and radiopharmaceutical solutions, state-of-the-art medical technology and a full range of services and support to medical facilities, in radiology, oncology, cardiology and neurology.
-
Quality management system
The integrated quality management system implemented by Synektik guarantees that the highest standards of our services are maintained at a stable level. The system, certified by TÜV NORD Polska, is compliant with ISO 9001 (quality management), ISO 27001 (information security management) and ISO 13485 for medical devices. Synektik Pharma, due to its business profile, operates on the basis of international standards of the so-called Good Manufacturing Practice (GMP) and applicable national standards.
-
Confidence
Synektik has been building trust in the market since 2001. Our expertise is based on world-proven solutions. The company’s strict specialisation, the experience and competence of its employees and the company’s policy ensure the quality of its services, products and customer relations.
-
European standards
The products and services provided by Synektik Group meet the requirements of European Union directives and comply with European standards.
-
Polmed and other memberships
Synektik is a member of the All-Poland Chamber of Commerce of Medical Devices POLMED, the largest and most representative organisation bringing together manufacturers and distributors operating on the Polish medical device market.
The Group is also a member of the Employers of Poland and the Polish Federation of Hospitals.
-
Awards and honour
Synektik Group has received a number of awards and honours, including: the title of Stock Exchange Company of the Year, a distinction in the Health Rankings organised as part of the Healthcare Forum, the Crystal Brussels Prize, and the title of NewConnect Company of the Year. Cezary Kozanecki, the CEO and founder, was honoured with the Wektor Pracodawców RP award for innovation in the development of special radiopharmaceuticals for the detection of specific conditions in PET/CT examinations and the title of Business Visionary awarded by the ‘Dziennik Gazeta Prawna’.
All awards and honours are summarised below.
Our partners
Our experience
We have been providing the highest quality medical technologies for 25 years.
25
Years of business
Operating in the medical industry since 2001
15
Years since going public
Listed on the Warsaw Stock Exchange since 2011
7
Countries of business
Operating in Poland, the Czech Republic, Slovakia, Lithuania, Latvia, Estonia and Ukraine
30m+
Donations in PLN
More than PLN 30m in grants for the development of new radiopharmaceuticals and IT products
The most important events in the activity of Synektik
We have been providing the highest quality medical technologies for 25 years.
Research and development
One of the Group’s strategic areas of activity is research and development in the field of radiopharmaceuticals used in oncological, neurological and cardiological diagnostics, as well as in areas related to IT solutions.
The Group’s Research and Development Centre is working on improving production processes and enhancing the quality of existing products used in PET diagnostics.
Cardiac-tracer and Syn2bio
The Group’s flagship research and development project was a cardio-tracer, an innovative radiopharmaceutical for non-invasive diagnosis of heart disease, in particular coronary artery disease. The cardio-tracer will be used to examine myocardial perfusion (MPI) using a method combining PET and computed tomography (PET-CT). The product is currently in phase III clinical trials.
In 2026, the Group’s R&D activities relating to the cardiac-tracer project were transferred to a new entity as well as searching for new, innovative radiopharmaceutical molecules, their further research, registration and final market launch as medicinal products. A new entity, Syn2bio SA, has been listed on the Warsaw Stock Exchange from 15th April 2026.
The impact of the Synektik Group activity onto the environment and the surroundings
Operational activity conducted by the Synektik Capital Group does not generate any significant impact on the natural environment. With regards to the production and distribution of radiopharmaceuticals, the Group follows strict rules and regulations concerning the management of raw materials as well as waste products and their utilisation.
Information regarding the human health and environmental impact related to the sources of ionising radiation.
The activity related to the sources of ionising radiation at Synektik SA and Synektik Pharma Sp. z o.o. does not have any negative impact on human health and the environment.
Synektik Group conduct regarding sources of ionising radiation strictly follows the conditions of the permit issued by the President of the National Atomic Energy Agency as well as the current legal requirements as per the Atomic Law Act. It also ensures that any environmental impact of the waste is minimised. The activity related to the sources of the ionising radiation does not result in releasing any radioactive substances into the environment.
Subsidised investments
The Synektik Group benefits from public and European subsidies. Details are available on our website (in Polish).
Reporting of adverse reactions and medical incidents
Synektik Group companies – Synektik SA and Synektik Pharma Sp. z o.o. – as responsible parties, are obliged, as part of their pharmacovigilance, to collect all information on adverse reactions that occur as a result of the use of the company’s medicinal products. This obligation follows directly from the provisions of the Pharmaceutical Law of 6 September 2001.
What is an adverse reaction?
It is any adverse and unintended effect of a medicinal product. Undesirable effects of medicinal products manufactured by Synektik SA and Synektik Pharma Sp. z o.o. can be reported at the following telephone number: +48 22 327 09 40 (24-hour voice mail) or contact: phv@synektik.com.pl.
More information on drug safety monitoring and specimen forms for reporting adverse reactions are available on the website of The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych).
Downloads
| Name | Action |
|---|---|
| Cezary Kozanecki - President of the Management Board of Synektik SA | Download |
| Dariusz Korecki - Vice President of the Management Board of Synektik SA | Download |
| Tomasz Wróbel - Member of the Management Board of Synektik SA | Download |
| Artur Ostrowski - Proxy of Synektik SA | Download |
| Przemysław Kozanecki - President of the Management Board of Synektik Pharma sp. z o.o. | Download |
| Krzysztof Bogdański - President of the Management Board of IT4KAN Sp. z o.o. | Download |
| Rafał Dunal - Vice President of the Management Board of IT4KAN Sp. z o.o. | Download |
